Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients

被引：0
|
作者：
Fizazi, K. [1 ]
Bernard-Tessier, A. [1 ]
Barthelemy, P. [2 ]
Utriainen, T. [3 ]
Roubaud, G. [4 ]
Flechon, A. [5 ]
van der Voet, J. C. M. [6 ]
Mescam, G. Gravis [7 ]
Ratta, R. [8 ]
Jones, R. H. [9 ]
Parikh, O. A. [10 ]
Tanner, M. M. E. [11 ]
Garratt, C. [12 ]
Nevalaita, L. [13 ]
Pohjanjousi, P. [13 ]
Ikonen, T. [13 ]
Antonarakis, E. S. [14 ]
Cook, N. [15 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] ICANS Inst Cancerol, Med Oncol, Strasbourg, France
[3] Univ Helsinki, Oncol, Cent Hosp, Helsinki, Finland
[4] Inst Bergonie, Med Oncol, Bordeaux, France
[5] Ctr Leon Berard, Med Oncol, Lyon, France
[6] James Cook Univ Hosp, Radiotherapy, Middlesbrough, Cleveland, England
[7] IPC Inst Paoli Calmettes, Med Oncol, Marseille, France
[8] Hop Foch, Med Oncol, Suresnes, France
[9] NHS Wales, Velindre Canc Ctr, Cardiff, Wales
[10] Lancashire Teaching Hosp NHS Fdn Trust, Royal Preston Hosp, Oncol, Preston, Lancs, England
[11] Tampere Univ Hosp Tays, R&D, Tampere, Finland
[12] Orion Corp Orion Pharma, R&D, Newbury NG1 1AH, Berks, England
[13] Orion Corp Orion Pharma, R&D, Espoo, Finland
[14] Johns Hopkins Univ, Med Oncol, Baltimore, MD USA
[15] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364MO
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [21] A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Rathkopf, Dana E.
    Slovin, Susan F.
    Autio, Karen A.
    Delacrur, Anthony
    Shelkey, Gregory
    Pisano, Katherine
    Hullings, Melanie
    DeNunzio, Mia
    Morris, Michael J.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [23] Phase-II-Studie bei Patienten mit metastasiertem kastrationsresistenten Prostatakarzinom (mCRPC)Phase II study with metastatic castration-resistant prostate cancer (mCRPC) patients
    H. Rexer
    M. Graefen
    Der Urologe, 2017, 56 (11): : 1468 - 1470
  • [24] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [25] BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY
    Erdal, E.
    Malhan, S.
    Oksuz, E.
    Benekli, M.
    Cag, C.
    Dane, F.
    Kabasakal, L.
    Kucuk, O.
    Sozen, T. S.
    Sar, C.
    Kahveci, B.
    VALUE IN HEALTH, 2016, 19 (07) : A725 - A726
  • [26] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [27] Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
    Smith, Matthew Raymond
    Sandhu, Shahneen Kaur
    Kelly, William Kevin
    Scher, Howard I.
    Efstathiou, Eleni
    Lara, Primo
    Yu, Evan Y.
    George, Daniel J.
    Chi, Kim N.
    Summa, Jason
    Kothari, Nishi
    Zhao, Xin
    Espina, Byron M.
    Ricci, Deborah S.
    Simon, Jason S.
    Tran, Namphuong
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
    Romano, P. Martin
    Roubaud, G.
    Lavaud, P.
    Cabart, M.
    Pages, A.
    Vasseur, D.
    Colomba, E.
    Cousin, S.
    Toulmonde, M.
    Grellety, T.
    Ajgal, Z. Castel
    Chabanon, R.
    Parpaleix, A.
    Buzzatti, G.
    Fizazi, K.
    Gomez-Roca, C. A.
    Italiano, A.
    Loriot, Y.
    Postel-Vinay, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1334 - S1334
  • [30] BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Hadfield, Matthew J.
    De Souza, Andre
    Golijanin, Dragan
    Wood, Roxanne
    Olszewski, Adam
    Holder, Sheldon L.
    El-Deiry, Wafik S.
    Aggarwal, Rahul
    Mega, Anthony
    Carneiro, Benedito A.
    CANCER RESEARCH, 2023, 83 (08)
12345